| Literature DB >> 29531576 |
Sebastian Polak1,2, Barbara Wiśniowska1, Aleksander Mendyk3, Adam Pacławski3, Jakub Szlęk3.
Abstract
Human heart electrophysiology is complex biological phenomenon, which is indirectly assessed by the measured ECG signal. ECG trace is further analyzed to derive interpretable surrogates including QT interval, QRS complex, PR interval, and T wave morphology. QT interval and its modification are the most commonly used surrogates of the drug triggered arrhythmia, but it is known that the QT interval itself is determined by other nondrug related parameters, physiological and pathological. In the current study, we used the computational intelligence algorithms to analyze correlations between various simulated physiological parameters and QT interval. Terfenadine given concomitantly with 8 enzymatic inhibitors was used as an example. The equation developed with the use of genetic programming technique leads to general reasoning about the changes in the prolonged QT. For small changes of the QT interval, the drug-related IKr and ICa currents inhibition potentials have major impact. The physiological parameters such as body surface area, potassium, sodium, and calcium ions concentrations are negligible. The influence of the physiological variables increases gradually with the more pronounced changes in QT. As the significant QT prolongation is associated with the drugs triggered arrhythmia risk, analysis of the role of physiological parameters influencing ECG seems to be advisable.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29531576 PMCID: PMC5817210 DOI: 10.1155/2018/3719703
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
The summary of the data set.
| Input number | Labels | Min | 1st quantile | Median | Mean | 3rd quantile | Max |
|---|---|---|---|---|---|---|---|
| (1) | CYP1A2 | 0 | 0 | 0 | 695159 | 0 | 11963910 |
| (2) | CYP2A6 | 0 | 0 | 0 | 0 | 0 | 0 |
| (3) | CYP2B6 | 0 | 0 | 0 | 86155 | 0 | 9129915 |
| (4) | CYP2C8 | 0 | 0 | 0 | 0 | 0 | 0 |
| (5) | CYP2C9 | 0 | 0 | 0 | 347459 | 0 | 16469809 |
| (6) | CYP2C18 | 0 | 0 | 0 | 0 | 0 | 0 |
| (7) | CYP2C19 | 0 | 0 | 0 | 179400 | 0 | 5511004 |
| (8) | CYP2D6 | 0 | 252231 | 399478 | 506695 | 676312 | 2185456 |
| (9) | CYP2E1 | 0 | 0 | 0 | 0 | 0 | 0 |
| (10) | CYP2J2 | 0 | 0 | 0 | 0 | 0 | 0 |
| (11) | CYP3A4 | 1552693 | 5716140 | 8459929 | 9833766 | 12016781 | 32307836 |
| (12) | CYP3A5 | 0 | 0 | 0 | 272853 | 0 | 13728653 |
| (13) | CYP3A7 | 0 | 0 | 0 | 0 | 0 | 0 |
| (14) | Gut_CYP2C9 | 8210 | 1430 | 10037.216 | 10089.122 | 10148.391 | 10388.032 |
| (15) | Gut_CYP2C19 | 0 | 0 | 0 | 299 | 0 | 7330 |
| (16) | Gut_CYP2D6 | 0 | 484.7 | 674.4 | 818.4 | 994.5 | 3156 |
| (17) | Gut_CYP2J2 | 0 | 0 | 0 | 0 | 0 | 0 |
| (18) | Gut_CYP3A4 | 11214 | 35540 | 55975 | 62911 | 80376 | 217447 |
| (19) | Gut_CYP3A5 | 0 | 0 | 0 | 807.2 | 0 | 55106.1 |
| (20) | Sex_Code | 0 | 1 | 1 | 0.7718 | 1 | 1 |
| (21) | Age | 19 | 25 | 28 | 28.39 | 32 | 52 |
| (22) | Weight | 44.52 | 69.43 | 78.31 | 79.04 | 89.17 | 127 |
| (23) | Height | 149.4 | 168.6 | 174.3 | 173.6 | 179.7 | 200.5 |
| (24) | BSA | 1.422 | 1.802 | 1.937 | 1.929 | 2.048 | 2.432 |
| (25) | Brain_Weight | 1040 | 1230 | 1354 | 1388 | 1524 | 2057 |
| (26) | Kidney_Weight | 164.1 | 269.1 | 325 | 329.1 | 382.6 | 752 |
| (27) | Liver_Weight | 1052 | 1544 | 1700 | 1740 | 1938 | 2699 |
| (28) | BMI | 16.13 | 22.87 | 26.22 | 26.19 | 28.8 | 45.31 |
| (29) | Cardiac_Output | 249.7 | 315.1 | 339.4 | 337.5 | 357.2 | 424.5 |
| (30) | Haematocrit | 32.12 | 38.99 | 41.73 | 41.46 | 43.68 | 51.05 |
| (31) | HSA | 35.11 | 42.88 | 45.74 | 45.75 | 48.57 | 58.08 |
| (32) | AGP | 0.3971 | 0.7137 | 0.8035 | 0.7982 | 0.8851 | 1.207 |
| (33) | Serum_Creatinine | 33.64 | 62.09 | 73.26 | 72.61 | 81.2 | 122.95 |
| (34) | GFR | 70.97 | 112.12 | 129.74 | 133.34 | 153.5 | 243.16 |
| (35) | Renal_Function | 0.59 | 0.92 | 1.079 | 1.089 | 1.271 | 1.87 |
| (36) | Cardiomyocyte_area | 652.5 | 1384.3 | 1701.1 | 1824.4 | 2146.8 | 5353.7 |
| (37) | Cardiomyocyte_volume | 1852 | 4494 | 5630 | 6217 | 7346 | 20339 |
| (38) | Sarcoplasmic_reticulum_volume | 111.1 | 269.6 | 337.8 | 373 | 440.7 | 1220.3 |
| (39) | Capacitance | 17.33 | 36.77 | 45.18 | 48.46 | 57.02 | 142.2 |
| (40) | String_length | 0.8772 | 1.1814 | 1.293 | 1.2878 | 1.4064 | 1.8619 |
| (41) | K | 3.053 | 4.079 | 4.268 | 4.261 | 4.451 | 5.363 |
| (42) | Na | 135.1 | 139.6 | 140.4 | 140.3 | 141.1 | 143.3 |
| (43) | Ca2 | 2.007 | 2.237 | 2.388 | 2.394 | 2.546 | 2.789 |
| (44) | IKr_inhibition | 0.0047 | 0.0484 | 0.1172 | 0.2378 | 0.3841 | 1 |
| (45) | IKs_inhibition | 0 | 1 | 1 | 0.0002684 | 0.0003 | 0.008 |
| (46) | INa_inhibition | 0 | 0.0003 | 0.0007 | 0.001493 | 0.0016 | 0.0353 |
| (47) | ICa_inhibition | 0 | 0.0009 | 0.0022 | 0.01782 | 0.0061 | 0.5217 |
| (48) | Stimulation_Period | 432 | 735 | 825 | 836.1 | 925 | 1570 |
|
| |||||||
| Output | dQTc | −15.707 | 1.713 | 6.591 | 10.572 | 14.69 | 78.142 |
Where CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2J2, CYP3A4, CYP3A5, CYP3A7, corresponding patients' abundance of cytochromes in the liver [pmol/mg of protein]; Gut_CYP2C9, Gut_CYP2C19, Gut_CYP2D6, Gut_CYP2J2, Gut_CYP3A4, Gut_CYP3A5, corresponding patients' abundance of cytochromes in the gut [nmol/small intestine]; Sex_Code, patients' gender [male = 0/female = 1]; Age, patients' age [years]; Weight, patients' weight [kg]; Height, patients' height [cm]; BSA, patients' body surface area [m2]; Brain_Weight, patients' brain weight [g]; Kidney_Weight, patients' kidney weight [g]; Liver_Weight, patients' liver weight [g]; BMI, patients' body mass index; Cardiac_Output, patients' cardiac output [L/h]; Haematocrit, patients' specific haematocrit [%]; HSA, AGP, patients' specific level of human serum albumin and alfa-acid glycoproteins in the plasma [g/L]; Serum_Creatinine, patients' specific creatinine level [μmol/L]; GFR, the Glomerular Filtration Rates of the simulated individual (mL/min/1.73 m2); Renal_Function, the ratio of individual's GFR to that of the normal value of 120 mL/min/1.73 m2 for male or 130 mL/min/1.73 m2 for female; Cardiomyocyte_area, patients' specific area of the cardiac myocyte [μm2]; Cardiomyocyte_volume, patients' specific volume of the cardiac myocyte [μm3]; Sarcoplasmic_reticulum_volume, patients' specific volume of the cardiac myocyte sarcoplasmic reticulum [μm3]; Capacitance, patients' specific cardiac myocyte electric capacitance [pF]; String_length, patients' specific thickness of the left heart wall [cm]; K, Na, Ca2, patients' specific concentration of ions in plasma [mM]; IKr_inhibition, IKs_inhibition, INa_inhibition, ICa_inhibition, patients' and drugs' specific ionic current inhibition; Stimulation_Period, time gaps between stimulaitons [ms]; dQTc, patients' QTc interval modification as compared against baseline.
Figure 1Workflow diagram presenting modeling methodology.
The results (NRMSE) of four algorithms applied on the eight input vectors. Corresponding coefficients of determination (R2) are shown in brackets.
| Input vector | Cubist | monmlp | RF | MARS |
|---|---|---|---|---|
| 9in_RMSE | 3.8 (0.93) | 4.0 (0.92) | 6.1 (0.85) | 5.8 (0.79) |
| 10in_MSE | 3.9 (0.93) | 3.9 (0.93) | 6.0 (0.83) | 6.0 (0.77) |
| 13in_MSE | 3.9 (0.93) | 3.9 (0.93) | 6.0 (0.83) | 5.9 (0.78) |
| 14in_RMSE | 4.0 (0.93) | 3.9 (0.93) | 6.1 (0.82) | 5.8 (0.78) |
| 18in_MSE | 3.7 (0.94) | 4.0 (0.93) | 6.2 (0.80) | 5.8 (0.78) |
| 19in_RMSE | 3.7 (0.94) | 4.0 (0.93) | 6.1 (0.81) | 5.8 (0.78) |
| 23in_MSE | 3.8 (0.93) | 4.0 (0.93) | 6.0 (0.84) | 5.8 (0.78) |
| 23in_RMSE | 3.8 (0.93) | 4.0 (0.93) | 6.0 (0.85) | 5.8 (0.78) |
Input vector selected for GP modeling.
| Orig input number | Equation ( | Label | Description |
|---|---|---|---|
| (1) | - | CYP1A2 | Liver CYP1A2 abundance [pmol/mg of protein] |
| (11) | - | CYP3A4 | Liver CYP3A4 abundance [pmol/mg of protein] |
| (14) | - | Gut_CYP2C9 | Gut CYP2C9 abundance [pmol/mg of protein] |
| (20) | - | Sex_Code | Patients' gender [male/female] |
| (22) | - | Weight | Patients' weight [kg] |
| (24) |
| BSA | Patients' body surface area [m2] |
| (29) | - | Cardiac_Output | Patient's cardiac output [L/h] |
| (41) |
| K | Patients' plasma potassium concentration [mM] |
| (42) |
| Na | Patients' plasma sodium concentration [mM] |
| (43) |
| Ca2 | Patients' plasma calcium concentration [mM] |
| (44) |
| IKr_inhibition | Patients' and drugs' specific IKr current inhibition [0–100%] |
| (45) |
| IKs_inhibition | Patients' and drugs' specific IKs current inhibition [0–100%] |
| (46) |
| INa_inhibition | Patients' and drugs' specific INa current inhibition [0–100%] |
| (47) |
| ICa_inhibition | Patients' and drugs' specific ICa current inhibition [0–100%] |
| (49) | dQTc | dQTc | Output (QTc interval modification as compared to baseline) |
Figure 2Predicted versus observed values for dQTc calculated according to (2).
Figure 3Changes in dQTc calculated according to (2), where the rest variables are of 1st quantile (0%). BSA = 1.422, K = 3.053, Na = 135.144, Ca2 = 2.007, IKr_inhibition = 0.005, IKs_inhibition = 0, INa_inhibition = 0, and ICa_inhibition = 0.
Figure 4Changes in dQTc calculated according to (2), where the rest variables are of 2nd quantile (25%). BSA = 1.802, K = 4.079, Na = 139.578, Ca2 = 2.237, IKr_inhibition = 0.048, IKs_inhibition = 0, INa_inhibition = 0, and ICa_inhibition = 0.001.
Figure 5Changes in dQTc calculated according to (2), where the rest variables are of 3rd quantile (50%). BSA = 1.937, K = 4.268, Na = 140.445, Ca2 = 2.388, IKr_inhibition = 0.117, IKs_inhibition = 0, INa_inhibition = 0.001, and ICa_inhibition = 0.002.
Figure 6Changes in dQTc calculated according to (2), where the rest variables are of 4th quantile (75%). BSA = 2.048, K = 4.451, Na = 141.094, Ca2 = 2.546, IKr_inhibition = 0.384, IKs_inhibition = 0, INa_inhibition = 0.002, and ICa_inhibition = 0.006.
Figure 7Changes in dQTc calculated according to (2), where the rest variables are of 5th quantile (100%). BSA = 2.432, K = 5.363, Na = 143.332, Ca2 = 2.789, IKr_inhibition = 1, IKs_inhibition = 0.008, INa_inhibition = 0.035, and ICa_inhibition = 0.522.
Figure 8Values of dQTcF predicted for IKr versus dQTcF predicted for ICa with matching inhibition values. Based on (2).